

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Jacobson Pharma Corporation Limited**

**雅各臣科研製藥有限公司**

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

### **BUSINESS UPDATE**

**“Landmark TAILORx Results, Published in  
The New England Journal of Medicine, Demonstrate the Oncotype DX  
Breast Recurrence Score® Test Definitively Identifies the 70% of  
Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy,  
and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving**

*Independently Led by the ECOG-ACRIN Research Group, TAILORx Prospective, Randomized Phase III Clinical Trial Results Presented in the Plenary Session at ASCO Annual Meeting*

*TAILORx-defined Cutoff for Definitively Determining Chemotherapy Benefit with Oncotype DX® Usher in a New Era in the Treatment of Early-stage Breast Cancer”<sup>1</sup>*

The board of directors of Jacobson Pharma Corporation Limited (the “**Company**” or “**Jacobson Pharma**”, together with its subsidiaries, “**Jacobson Pharma Group**”) is pleased to share that the Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, successfully defined the benefit of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score® results of 11 to 25. The long-awaited results of the TAILORx study, the largest ever breast cancer treatment trial, sponsored by the National Cancer Institute (NCI), and led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), provided definitive evidence that the Oncotype DX Breast Recurrence Score test<sup>(note a)</sup> identified 70 per cent of early-stage breast cancer patients<sup>(note b)</sup> who received no benefit from chemotherapy, and can be effectively treated with endocrine therapy alone. Additionally, the trial established that chemotherapy may provide life-saving benefit to 30 per cent of patients.

1. Source: J.A. Sparano et. al (2018). ‘Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer’. *The New England Journal of Medicine* 10.1056 (To read the article, please visit: <https://www.nejm.org/doi/full/10.1056/NEJMoa1804710>)

The TAILORx results were published on 3 June 2018 in *The New England Journal of Medicine* in conjunction with a presentation during the Plenary Session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, United States.

The TAILORx trial was independently designed and conducted by ECOG-ACRIN under the sponsorship of the NCI, part of the National Institutes of Health. All major cancer clinical research groups with trial sites in the United States, Canada, Ireland, Peru, New Zealand and Australia participated in the study.

Breast cancer is one of the most common types of cancerous disease and approximately 268,000<sup>2</sup> new cases were found in China in 2015. Closer to home, there were approximately 4,000<sup>3</sup> and 200<sup>4</sup> new cases found in Hong Kong and Macau in 2015 respectively.

As Jacobson Pharma Group has been the exclusive distributor of Genomic Health<sup>(note c)</sup> in Hong Kong and Macau for 10 years, the Company is confident that together with its close collaboration with Genomic Health and our in-depth experiences in the relevant markets, it will be able to continue expanding business opportunities emerging in this arena.

The Company assumes no responsibility from the scientific claims and conclusions of these findings.

*Note a:*

*About Oncotype DX<sup>®</sup>*

Jacobson Pharma Group is the exclusive distributor of Genomic Health for the Oncotype DX Test in Hong Kong and Macau. The Oncotype DX<sup>®</sup> portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score<sup>®</sup> test, is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score<sup>®</sup> test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score<sup>®</sup> test predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 900,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit [www.OncotypeIQ.com](http://www.OncotypeIQ.com), [www.MyBreastCancerTreatment.org](http://www.MyBreastCancerTreatment.org) or [www.MyProstateCancerTreatment.org](http://www.MyProstateCancerTreatment.org)

*Note b:*

Patients enrolled in the TAILORx trial had hormone-receptor – positive, human epidermal growth factor receptor 2 (HER2) – negative, axillary node – negative breast cancer; and met National Comprehensive Cancer Network guidelines for the recommendation or consideration of adjuvant chemotherapy in the findings.

2. Source: Report of Incidence and Mortality from China Cancer Registries
3. Source: Hong Kong Cancer Registry
4. Source: Annual Report of the Macao Cancer Registry

*Note c:*  
*About Genomic Health*

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease, one of the greatest issues in healthcare today. Its Oncotype DX® gene expression tests have been used to guide treatment decisions for more than 900,000 cancer patients worldwide. The company is based in Redwood City, California, United States, with international headquarters in Geneva, Switzerland. For more information, please visit, [www.GenomicHealth.com](http://www.GenomicHealth.com).

*Note:* Technical terms contained in this announcement are transcribed from the captioned article published in *The New England Journal of Medicine*. Readers of the Chinese version of the announcement are advised to read in conjunction with the English version of the announcement as well the article itself, which can be accessed at <https://www.nejm.org/doi/full/10.1056/NEJMoa1804710>.

By order of the Board  
**Jacobson Pharma Corporation Limited**  
**WU Lai King**  
*Company Secretary*

Hong Kong, 13 June 2018

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Wong Chi Kei, Ian as independent non-executive Directors.*